Despite the homogeneous tumor presence of BRCA2 LOH, the MLH1/PMS2-deficient region exhibited a higher mutation burden, potentially indicating a distinct tumor evolutionary trajectory. This evidence concerns the gene BRCA2 and neoplasm.